News

A poster presented at the 2024 ASCP Annual Meeting discusses the results of a systematic literature review.

Answer a quick question on psychedelics!

Learn more about the potential of MDMA-assisted psychotherapy.

Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.

Research on MDD treatments seltorexant and Spravato (esketamine) CIII nasal spray shared at 2024 ASCP Annual Meeting.

How does the Voice Lab relate to psychotherapy?

An expert shares 7 principles for clinicians to consider when prescribing multiple medications for a patient.

The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.

Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.

Joseph F. Goldberg, MD, gives a preview of his upcoming panel presentation at the 2024 ASCP Annual Meeting.

Anita H. Clayton, MD, welcomes us all to the 2024 ASCP Annual Meeting!

Onyda XR is the first and only liquid nonstimulant ADHD medication approved in the US and the only approved nonstimulant ADHD medication with nighttime dosing.

What can 2 recent deaths show us about depression and suicidality?

An analysis presented at the ASCP Annual Meeting explored the safety and tolerability of the treatment for alcohol and tobacco use disorders.

Clinicians should carefully weigh the risks and benefits of each prescribed medication for an older adult with neuropsychiatric diseases and periodically review all prescribed medications. Learn more here.

Answer a quick question on psychedelics!

A poster at the 2024 ASCP Annual Meeting shared data from 3 randomized clinical trials on the safety and tolerability of this treatment combination.

From populations to patients.

An expert discusses the potential of smartphones as treatment measurement tools at the 2024 ASCP Annual Meeting.

Improving cognitive function is a primary goal of brain injury rehabilitation and is made possible through the process of neuroplasticity.

An expert discusses the role of cognition in bipolar disorder and the potential of modafinil as a treatment for it at the 2024 ASCP Annual Meeting.

An expert shares some lessons learned from prior research on the treatment and suggestions for a way forward at the 2024 ASCP Annual Meeting.

Answer a quick question on psychedelics!

An expert shares highlights from her panel presentation at the 2024 ASCP Annual Meeting.

What are the risks and benefits of antipsychotic polypharmacy for the treatment of schizophrenia?

In what ways can we make peace?

Investigators at McLean Hospital found 61% and 45% of individuals still experiencing binge-eating disorder after 2.5 and 5 years after their initial diagnoses, respectively.

Attending the 2024 ASCP Annual Meeting? Be sure to catch these upcoming poster presentations.

How can we enhance our lithium research?

"...yet all the passengers filed out saying, “Thank you! We didn’t know a doctor would still help in an emergency.” But I was like the heroes on the evening news declaring, “No big deal. Just doing my job,” and meaning it..."